| pubmed-article:15190527 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C0018801 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C0025663 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C0018787 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C0018684 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C1317973 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C0699733 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C0183683 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C0344211 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C1521721 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C0206034 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C0027976 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C1704771 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C2699007 | lld:lifeskim |
| pubmed-article:15190527 | lifeskim:mentions | umls-concept:C1171411 | lld:lifeskim |
| pubmed-article:15190527 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:15190527 | pubmed:dateCreated | 2004-6-10 | lld:pubmed |
| pubmed-article:15190527 | pubmed:abstractText | Heart failure remains a progressive disease with incremental morbidity and mortality despite optimal medical therapy. A growing body of evidence suggests that progressive left ventricular (LV) remodeling is directly related to a deterioration in LV performance and untoward clinical outcomes for heart failure patients. Preclinical and early phase I clinical studies with the CorCap Cardiac Support Device (CSD), a passive cardiac support device that prevents cardiac remodeling, have shown that it is safe and is associated with improvements in LV structure and function, as well as patient symptomatology. | lld:pubmed |
| pubmed-article:15190527 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15190527 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15190527 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15190527 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15190527 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:15190527 | pubmed:issn | 1071-9164 | lld:pubmed |
| pubmed-article:15190527 | pubmed:author | pubmed-author:StarlingRanda... | lld:pubmed |
| pubmed-article:15190527 | pubmed:author | pubmed-author:MannDouglas... | lld:pubmed |
| pubmed-article:15190527 | pubmed:author | pubmed-author:AckerMichael... | lld:pubmed |
| pubmed-article:15190527 | pubmed:author | pubmed-author:SabbahHani... | lld:pubmed |
| pubmed-article:15190527 | pubmed:author | pubmed-author:JessupMariell... | lld:pubmed |
| pubmed-article:15190527 | pubmed:author | pubmed-author:KuboSpencer... | lld:pubmed |
| pubmed-article:15190527 | pubmed:author | pubmed-author:Acorn... | lld:pubmed |
| pubmed-article:15190527 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15190527 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:15190527 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15190527 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15190527 | pubmed:pagination | 185-92 | lld:pubmed |
| pubmed-article:15190527 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15190527 | pubmed:meshHeading | pubmed-meshheading:15190527... | lld:pubmed |
| pubmed-article:15190527 | pubmed:meshHeading | pubmed-meshheading:15190527... | lld:pubmed |
| pubmed-article:15190527 | pubmed:meshHeading | pubmed-meshheading:15190527... | lld:pubmed |
| pubmed-article:15190527 | pubmed:meshHeading | pubmed-meshheading:15190527... | lld:pubmed |
| pubmed-article:15190527 | pubmed:meshHeading | pubmed-meshheading:15190527... | lld:pubmed |
| pubmed-article:15190527 | pubmed:meshHeading | pubmed-meshheading:15190527... | lld:pubmed |
| pubmed-article:15190527 | pubmed:meshHeading | pubmed-meshheading:15190527... | lld:pubmed |
| pubmed-article:15190527 | pubmed:meshHeading | pubmed-meshheading:15190527... | lld:pubmed |
| pubmed-article:15190527 | pubmed:meshHeading | pubmed-meshheading:15190527... | lld:pubmed |
| pubmed-article:15190527 | pubmed:meshHeading | pubmed-meshheading:15190527... | lld:pubmed |
| pubmed-article:15190527 | pubmed:meshHeading | pubmed-meshheading:15190527... | lld:pubmed |
| pubmed-article:15190527 | pubmed:meshHeading | pubmed-meshheading:15190527... | lld:pubmed |
| pubmed-article:15190527 | pubmed:meshHeading | pubmed-meshheading:15190527... | lld:pubmed |
| pubmed-article:15190527 | pubmed:meshHeading | pubmed-meshheading:15190527... | lld:pubmed |
| pubmed-article:15190527 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15190527 | pubmed:articleTitle | Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure. | lld:pubmed |
| pubmed-article:15190527 | pubmed:affiliation | Center for Heart Failure, Baylor College of Medicine, Houston, Texas 77030, USA. | lld:pubmed |
| pubmed-article:15190527 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15190527 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15190527 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:15190527 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15190527 | lld:pubmed |
